The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Open accessAbstract
We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V 1a , V 1b and V 2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT). In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents. We also present our recent findings on the design of fluorescent ligands for V 1b receptor localisation and for OT receptor dimerisation. We note the exciting discoveries regarding two novel naturally occurring analogues of OT. Recent reports of a selective VP V 1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field. To date, only two nonpeptides, the V 2 /V 1a antagonist, conivaptan and the V 2 antagonist tolvaptan have received Food and Drug Administration approval for clinical use. The development of nonpeptide AVP V 1a , V 1b and V 2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer. A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour. A number of the nonpeptide ligands that were not successful in clinical trials are proving to be valuable as research tools. Peptide agonists and antagonists continue to be very widely used as research tools in this field. In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, especially with regard to receptor selectivity and species differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although these compounds bind selectively to their respective receptors in rodents, they have now been shown to exhibit relatively high affinities for both OXTR and AVPR1a in primates (27,28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“Simply comparing the binding characteristics of the most common ligands for the human and rat OT and AVP receptors reveals considerable variation in pharmacological properties across species (28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“For example, studies employing recombinant expression systems to examine selectivity of human, rat, and mouse OT and AVP receptors have shown that only the human OTR is selective for OT using a standard criterion [34; 35] (Table 1).”
From Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery (2018) · cites this paper as [35]
In the citing paper
“The limited information on the distributions of OTR and V1aR in primate neural tissue is due in part to the lower selectivity for radioligands targeting OTR (125I-OVTA) and V1aR (125I-LVA) autoradiography, relative to high selectivity of radioligands for these receptors in rodents, as well as the promiscuous binding profile of both radioligands for OTR and V1aR (Freeman et al., 2014a, 2014b; Man”
From Neuropeptide diversity and the regulation of social behavior in New World primates (2016) · cites this paper as Manning et al., 2012
In the citing paper
“There was also no difference in AVP levels, suggesting no peripheral cross-reactivity, which is more likely to occur with higher levels of oxytocin exposure.71”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium's Role in Mechanotransduction during Muscle Development
Damm, T. B., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,552
Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide
Merrifield, R. B. (1963) · Journal of the American Chemical Society · doi:10.1021/ja00897a025 · Cited by 7,825
Inositol Trisphosphate, a Novel Second Messenger in Cellular Signal Transduction
Berridge, M. J., & Irvine, R. F. (1984) · Nature · doi:10.1038/312315a0 · Cited by 6,086
A highly sensitive adenylate cyclase assay
Salomon, Y., Londos, C., & Rodbell, M. (1974) · Analytical Biochemistry · doi:10.1016/0003-2697(74)90222-x · Cited by 4,135
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Stewart, J. M. (1976) · Journal of Macromolecular Science Part A - Chemistry · doi:10.1080/00222337608068099 · Cited by 1,770
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martínez, J., & Khrestchatisky, M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,523
Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215
Research works printed but not linked: 13
- Manning M, 1981, The Pituitary, 265
- Manning M, 1985, Development of Selective Agonists and Antagonists of Vasopressin and Oxytocin, 131
- Manning M, 1991, Vasopressin, 297
- Manning M, 2005, Peptides 2004, 101
- Lebl M, 1988, Handbook of Neurohypophyseal Hormone Analogs, 17
- Jard S, 1998, Adv Exp Med Biol, 1
- 10.1210/en.137.9.3906 · DOI
- Wisniewski K, 2010, Peptides 2010, 306
- Manning M, 2010, Peptides 2010, 366
- Guillon G, 2007, Peptides 2006, 742
- 10.1021/jm010526 · DOI
- Mimoun MB, 2001, Peptides 2000, 589
- Reichert J, 2010, Development Trends for Peptide Therapeutics
Cited by
Sorted by citations
Items 301–400 of 429
Grieb, Z. A., Cross, E. A., & Albers, H. E. (2022) · Physiology & Behavior · doi:10.1016/j.physbeh.2022.113828 · Cited by 7
Vasopressin acts as a synapse organizer in limbic regions by boosting PSD95 and GluA1 expression
Zhang, L., Padilla‐Flores, T., Hernández, V. S., Zetter, M. A., Campos‐Lira, E., Escobar, L. I., Millar, R. P., & Eiden, L. E. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13164 · Cited by 5
Borie, A. M., Dromard, Y., Chakraborty, P., Fontanaud, P., André, E. M., François, A., Colson, P. H., Muscatelli, F., Guillon, G., Desarménien, M. G., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101781 · Cited by 6
Self-citationPífano, M., Garona, J., Sobol, N. T., Albertó, M., Alonso, D. F., & Ripoll, G. V. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0178 · Cited by 6
Sucrose intake by rats affected by both intraperitoneal oxytocin administration and time of day
Rehn, S., Raymond, J. S., Boakes, R. A., & Bowen, M. T. (2021) · Psychopharmacology · doi:10.1007/s00213-021-06014-3 · Cited by 6
Vasopressin V1a and V1b receptor modulators: a patent review (2012 – 2014)
Ślusarz, M. J. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1026257 · Cited by 6
Cheng, Y.-J., Zan, G., Deng, Y.-Z., Deng, D., Wu, M., Chai, J., Wang, Y.-J., Liu, J., & Zhao, M. (2025) · Nature Communications · doi:10.1038/s41467-025-59859-z · Cited by 6
Molecular basis of antagonism of the dimeric human arginine vasopressin receptor 1A
Zhong, P., Chu, B., Yu, Z., Qiao, Y., Ding, Y., Zhang, Y., & Wu, X. (2026) · Nature Communications · doi:10.1038/s41467-026-68331-5 · Cited by 5
Nakamura, K., Karasawa, K., Yasui, M., & Nuriya, M. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c00452 · Cited by 5
Huang, C., Jia, Z., Tang, C., Hou, W., Li, L., Guo, X., Zhang, L., Qu, Y., Li, Y., Li, Y., et al. (2024) · Neuroendocrinology · doi:10.1159/000540938 · Cited by 6
Hennessy, M. B., Tai, F., Carter, K. A., Watanasriyakul, W. T., Gallimore, D. M., Molina, A. L., & Schiml, P. A. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.112710 · Cited by 5
Gilles, N. (2023) · Biology · doi:10.3390/biology12040544 · Cited by 5
A systematic review of the pharmacological modulation of autobiographical memory specificity
Cawley, E., Piazza, G. G., Das, R., & Kamboj, S. K. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.1045217 · Cited by 5
Oxytocin testing and reproductive health: Status and clinical applications
Gruson, D. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.10.016 · Cited by 5
Cyclic Peptides in Modern Drug Discovery: Trends and Therapeutic Directions
Thite, T., Iyer, K. A., Jain, P., Sasso, J. M., Tenchov, R., Murmu, S., Surendranath, M., Maind, A., Balande, U., & Zhou, Q. A. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01522 · Cited by 6
Effects of intracerebroventricular arginine vasotocin on a female amphibian proceptive behavior
Boyd, S. K. (2019) · Journal of Comparative Physiology A · doi:10.1007/s00359-019-01340-6 · Cited by 4
Sobol, N. T., Solernó, L. M., Llavona, C., Alonso, D. F., & Garona, J. (2023) · World Journal of Oncology · doi:10.14740/wjon1715 · Cited by 4
Kwiatkowska, A., Lewandowska, M., Borovičková, L., Slaninová, J., Lammek, B., & Prahl, A. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12093 · Cited by 5
AVPR1b variation and the emergence of adaptive phenotypes in Platyrrhini primates
Fam, B. S. D. O., Reales, G., Vargas‐Pinilla, P., Paré, P., Viscardi, L. H., Sortica, V. A., Felkl, A. B., Franco, Á. D. O., Lucion, A. B., Costa-Neto, C. M., et al. (2019) · American Journal of Primatology · doi:10.1002/ajp.23028 · Cited by 5
Patel, S., Volpe, A. B., Awwad, S., Schätzlein, A. G., Haider, S. M., Liu, B., & Uchegbu, I. F. (2020) · Scientific Reports · doi:10.1038/s41598-020-64070-9 · Cited by 4
Veulens, A. D. L. N., Ginarte, Y. M. Á., Fernandez, R. E. R., Leclerc, F., & Montero, L. A. (2022) · Journal of Molecular Modeling · doi:10.1007/s00894-021-05022-6 · Cited by 4
Almeida, O., Félix, A. S., & Oliveira, R. F. (2022) · acta ethologica · doi:10.1007/s10211-022-00404-2 · Cited by 4
Cardiac arrest caused by the application of pituitrin during laparoscopic myomectomy
Li, J.-R., Liao, X., Lv, F.-Q., & Li, H. (2023) · BMC Women s Health · doi:10.1186/s12905-023-02255-w · Cited by 4
Misawa, T., & Demizu, Y. (2023) · ChemistrySelect · doi:10.1002/slct.202300408 · Cited by 4
Scaled-up Synthesis and Characterization of Oxytocin Trisulfide
Hammer, R. P., Butrie, M. A., Davidson, K., Goldblatt, P. T., Schrader, A. M., Dalluge, J. J., Becker, A. R., & Bárány, G. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10580-9 · Cited by 4
The Current Status of Drug Discovery for the Oxytocin Receptor
Nashar, P. E., Whitfield, A. A., Mikušek, J., & Reekie, T. A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1759-5_10 · Cited by 4
Fluorescent Peptide Tracers for Simultaneous Oxytocin Receptor Activation and Visualization
Perisic, M., Kalaba, P., Gormal, R. S., Zupančič, M., Wolf, A., Juračić, M., Kremsmayr, T., Meunier, F. A., Langer, T., Gruber, C. W., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202515180 · Cited by 3
Pierce, M. L., French, J. A., & Murray, T. F. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109832 · Cited by 3
Peptide drugs application in metabolic diseases and discovery strategies
Bin, T. E. N. G., Junfeng, L. I., & Ren, P. (2022) · Journal of Holistic Integrative Pharmacy · doi:10.1016/s2707-3688(23)00063-8 · Cited by 3
Tregeagle, D. F. L., Doherty, C., Callis, T. B., & Kassiou, M. (2025) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2025.04.004 · Cited by 3
Ostrovitsa, N., Williams, C., Raabe, K., McLean, J. T., Muttenthaler, M., & Scanlan, E. M. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202501372 · Cited by 3
Neurobiological mechanisms underlying oxytocin-mediated parental behavior in rodents
Inada, K. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.04.001 · Cited by 3
Fortaleza, E. A. T., Busnardo, C., Fassini, A., Belém-Filho, I. J. A., Almeida‐Pereira, G., Antunes‐Rodrigues, J., & Corrêa, F. M. D. A. (2019) · Stress · doi:10.1080/10253890.2019.1660771 · Cited by 3
Synthesis of new vasotocin analogues: effects on renal water and ion excretion in rats
Кутина, А. В., Marina, A. S., Eliseev, I. I., Titov, M. I., & IuV, N. (2013) · Journal of Peptide Science · doi:10.1002/psc.2495 · Cited by 3
Arginine Vasopressin: An Immunoregulatory Hormone
Quintanar‐Stephano, A., Organista‐Esparza, A., Chavira‐Ramírez, R., Campos‐Rodríguez, R., Berczi, I., & Kovács, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801770-8.00005-7 · Cited by 3
TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor
Koga, K., Yoshinaga, M., Uematsu, Y., Nagai, Y., Miyakoshi, N., Shimoda, Y., Fujinaga, M., Minamimoto, T., Zhang, M.-R., Higuchi, M., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232942 · Cited by 3
Bowen, M. T., Liu, J., & Buisman‐Pijlman, F. T. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800634-4.00008-1 · Cited by 3
Modzelewska, B., Jóźwik, M., Jóźwik, M., Tylicka, M., & Kleszczewski, T. (2019) · Pharmacological Reports · doi:10.1016/j.pharep.2019.05.003 · Cited by 3
Liutkevičiūtė, Z., & Gruber, C. W. (2016) · doi:10.1002/9781118760369.ch1 · Cited by 3
Oliveira, P., Soares, M. C., & Trigo, S. (2024) · Hormones and Behavior · doi:10.1016/j.yhbeh.2024.105646 · Cited by 4
Aspesi, D., Varatharajah, A., Cioffi, L., Diviccaro, S., Caruso, D., Becke, N., Lalonde, J., Perreault, M. L., Melcangi, R. C., MacLusky, N. J., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2600302123 · Cited by 2
Vasopressin: a possible link between hypoxia and hypertension
Szczepanska‐Sadowska, E. K., & Żera, T. (2022) · Exploration of Medicine · doi:10.37349/emed.2022.00103 · Cited by 2
Nagamine, R., Konno, N., Nakamachi, T., Matsubara, H., & Matsuda, K. (2024) · Peptides · doi:10.1016/j.peptides.2024.171239 · Cited by 2
Martínez‐Hernández, J., Garriga, F., Ahmad, A., Padilla, L., Maside, C., Bonet, S., Barranco, I., Roca, J., Pastor, L. M., & Yeste, M. (2025) · Andrology · doi:10.1111/andr.70123 · Cited by 2
Oxytocin receptor antagonists and their clinical application
Tsirkin, V. I., Трухина, С. И., Trukhin, A. N., Khlybova, S., & Anisimov, K. Y. (2018) · Russian Bulletin of Obstetrician-Gynecologist · doi:10.17116/rosakush20181805116 · Cited by 2
Jiménez, A., Jiménez, P., Inoue, K., Young, L. J., & González‐Mariscal, G. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13236 · Cited by 2
Guastella, A. J., Alvares, G. A., Hickie, I. B., Chan, H., Chen, T. F., & Banati, R. B. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.03.005 · Cited by 2
Borie, A. M., Dromard, Y., Dufner, D., Pollozi, E., Huzard, D., Tömböli, C., Olma, A., Manning, M., Colson, P. H., Guillon, G., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/800425 · Cited by 2
Self-citationIntranasal oxytocin administration rescues neonatal thermo-sensory deficit in mouse model of AutismPreprint
Prato, L. C. D., Abdallah, D., Point, V., Schaller, F., Pallesi‐Pocachard, E., Montheil, A., Canaan, S., Gaïarsa, J., Muscatelli, F., & Matarazzo, V. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/869487 · Cited by 2
Dubey, P., Fang, Y., Tukei, K. L., Kuila, S., Liu, X., Sahota, A., Frolova, A. I., Reinl, E. L., Malik, M., England, S. K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.28.582600 · Cited by 2
Buchholz, R., Dodd, C. E., & Heppard, J. M. (2018) · International Journal of Pest Management · doi:10.1080/09670874.2018.1478467 · Cited by 1
Hormones and the Regulation of Neuronal Voltage-Sensing Ion Channels
Lyons, D. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00011-0 · Cited by 1
The Vasopressin V1A Receptor and Aggression
Tan, O., & Bowen, M. T. (2023) · Springer eBooks · doi:10.1007/978-3-030-98711-4_90-1 · Cited by 2
Arginine vasopressin potentiates inspiratory bursting in hypoglossal motoneurons of neonatal mice
Bolte, K., Wealing, J., & Revill, A. (2023) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2023.104087 · Cited by 1
Fusani, B., Ramos, A., Cardoso, S. D., & Gonçalves, D. (2025) · Hormones and Behavior · doi:10.1016/j.yhbeh.2025.105728 · Cited by 1
Sommer, E., & Caldwell, H. K. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138409 · Cited by 1
Kamikawa, A. (2025) · Endocrinology · doi:10.1210/endocr/bqaf151 · Cited by 1
Zhang, W., Huang, C., Liu, J., Lu, L., Bai, Y., Sun, Y., Zhang, L., Ren, L., Huang, K., Yan, S., et al. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115984 · Cited by 1
Rajapaksha, D. C., Wadhi, T., Spitz, M., Segar, V., Nipu, N., Trudeau, V. L., & Mennigen, J. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1771879 · Cited by 1
Early life adversity, oxytocin system alterations, and addiction vulnerability: a narrative review
Saboory, E., Ahmadian-Moghadam, S., & Mehranfard, N. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07027-6 · Cited by 2
[Oxytocin, the hormone that everyone uses and that few know].
López-Ramírez, C. E., Arámbula-Almanza, J., & Pulido, E. E. C. (2014) · PubMed · Cited by 1
Rol Modulador de la Oxitocina en la Interacción Social y el Estrés Social
Flórez-Acevedo, S., & Cárdenas, F. P. (2017) · Universitas Psychologica · doi:10.11144/javeriana.upsy15-5.rmoi · Cited by 1
An Octopus-Derived Peptide with Antidiuretic Activity in Rats
Kim, Y., Lee, J. H., Jung, S.-H., Kim, K. H., Choi, C., Jo, S., & Woo, D. H. (2022) · Marine Drugs · doi:10.3390/md20050328 · Cited by 1
Oxytocin Verbindungen zur oralen Behandlung von Bauchschmerzen
Kremsmayr, T., Schober, G., Kaltenböck, M., Hoare, B. L., Brierley, S. M., & Muttenthaler, M. (2024) · Angewandte Chemie · doi:10.1002/ange.202415333 · Cited by 1
Alacreu‐Crespo, A., Olié, É., Manière, M., Deverdun, J., Bars, E. L., Corbani, M., Guillon, G., & Courtet, P. (2025) · BMC Neuroscience · doi:10.1186/s12868-025-00963-7 · Cited by 1
Self-citationNew Vistas of Old Terrains: Magnocellular Vasopressin and the Neuroendocrine Response to Stress
Antoni, F. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813156-5.00019-4 · Cited by 1
Yugar‐Toledo, J. C., de Faria, A. P., & Moreno, H. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-59918-2_8 · Cited by 1
Lu, R., Wu, C., Patil, A., & Wu, H. (2019) · doi:10.1002/9783527344406.ch16 · Cited by 1
Lozić, M., & Ludwig, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_145 · Cited by 1
A vasopressin circuit that modulates sex-specific social interest and anxiety-like behavior in micePreprint
Rigney, N., Campos‐Lira, E., Kirchner, M. K., Wei, W., Belkasim, S., Beaumont, R., Singh, S. P., Vries, G. J. D., & Petrulis, A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.06.564847 · Cited by 1
Manière, M. (2015) · theses.fr (ABES) · doi:10.70675/0be8e854za3f5z48bcz81c6zbe779562a135 · Cited by 1
Düsing, R., Mattie Tops, A., & Quirin, M. (2015) · Peptides · doi:10.1016/j.peptides.2015.06.008
Cross-talk between the Oxytocin and Vasopressin Systems in the Brian: Roles in Social Behavior
Song, Z. (2016) · Digital Archive @ GSU · doi:10.57709/7996120
Solution structure of kalata B7
Daly, N. L., Elliott, A. G., & Craik, D. J. (2013) · Worldwide Protein Data Bank · doi:10.2210/pdb2m9o/pdb
Rapid Estrogenic Mediation of Oxytocin in The Regulation of Social Recognition in Female Mice
Paletta, P. (2018) · The Atrium (University of Guelph)
Oxytocin receptor agonists and their clinical application
Tsirkin, V. I., Трухина, С. И., Trukhin, A. N., Khlybova, S., & Anisimov, K. Y. (2018) · Russian Bulletin of Obstetrician-Gynecologist · doi:10.17116/rosakush201818421
Future perspective on peptide therapeutics
Manning, M., Misicka, A., Bańkowski, K., & Verlander, M. S. (2015) · doi:10.4155/fseb2013.14.104
Self-citationThe Effect of Birth on Neural Activation in the Rodent Brain
Hoffiz, Y. C. (2022) · Digital Archive @ GSU · doi:10.57709/17328404
Estudo do enriquecimento ambiental na recompensa e na modulação do sistema de oxitocina.
Rae, M. B. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2020.tde-24012020-113021
The Mechanism of the Solute-Free Water Reabsorption Increase in the Rat Kidney by Oxytocin Saluresis
Natochin, Y. V., Ei, S., & Bogolepova, A. E. (2021) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672921020113
Pharmacological Characterisation of Novel Oxytocin and Vasopressin Receptor Ligands
Gulliver, D. W. (2021) · The Sydney eScholarship Repository (The University of Sydney)
Intracerebral Delivery of an OTR Antagonist and Subsequent Behavioral Testing in Prairie Voles
Hirota, Y., Otsuki, C., Kamura, E., & Mitsui, S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1759-5_16
岩崎, 弘., 関根, 威., 須江, 洋., 宮本千佳子, Morita, M., 井上, 聖., & 中山, 和. (2007) · てんかん研究
Lozić, M., & Ludwig, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_10071
Lozić, M., & Ludwig, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_10071-1
Desenho, síntese e caracterização funcional de análogos de oxitocina
da Silva, A. L. B. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2021.tde-10052021-133033
Lozić, M., & Ludwig, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_145-1
Gokula, V., Terrero, D., & Joe, B. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01226-0
Raby, W. N., Heller, M., Milliaressis, D., Choi, C. J., Basaraba, C. N., LEVIN, F. R., Church, S., Pavlicová, M., & Nunes, E. V. (2023) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2023.100158
Extracellular sodium regulates fibroblast growth factor 23 (FGF23) formationPreprint
Radványi, Z., Yoo, E. J., Kandasamy, P., Salas-Bastos, A., Monnerat, S., Refardt, J. C., Christ‐Crain, M., Hayashi, H., Kondo, Y., Jantsch, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.23.546282
The Vasopressin V1A Receptor and Aggression
Tan, O., & Bowen, M. T. (2023) · Springer eBooks · doi:10.1007/978-3-031-31547-3_90
Arakawa, H., & Higuchi, Y. (2023) · Springer eBooks · doi:10.1007/978-3-031-42383-3_6
No impairment of contextual fear memory consolidation by oxytocin receptor antagonism in male rats
Sherman, E. R., Li, J., & Cahill, E. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114545
Orav, E., Kokinovic, B., Teppola, H., Siimon, M., Lauri, S. E., & Hartung, H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110068
Current possibilities and prospects of tocolytic therapy
Kiryanova, A. O., & Murashko, A. V. (2024) · V F Snegirev Archives of Obstetrics and Gynecology · doi:10.17816/aog626529
Strategy for Construction of Homogeneous Glycoproteins in Mammalian Cells
Lee, C., Li, H., Hyun, J. Y., & Shin, I. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00361
Predicting oxytocin binding dynamics in receptor genetic variants through computational modeling
Dubey, P., Fang, Y., Tukei, K. L., Kuila, S., Liu, X., Sahota, A., Frolova, A. I., Reinl, E. L., Malik, M., England, S. K., et al. (2025) · npj Women s Health · doi:10.1038/s44294-025-00058-y
Fluoreszenzmarkierte Peptidtracer zur simultanen Aktivierung und Bildgebung des Oxytocinrezeptors
Perisic, M., Kalaba, P., Gormal, R. S., Zupančič, M., Wolf, A., Juračić, M., Kremsmayr, T., Meunier, F. A., Langer, T., Gruber, C. W., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202515180
Metadata
- Authors
- Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G.
- Affiliations
- University of Toledo (US)
- University of Warsaw (PL)
- Lodz University of Technology (PL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Manning, M.
- Venue
- Journal of Neuroendocrinology
- Publisher
- Wiley
- Published
- 2012-03-26
- Volume
- 24
- Issue
- 4
- Pages
- 609-628
- ISSN
- 0953-8194 (ISSN-L)
- 1365-2826
- PMC
- PMC3490377
- OpenAlex
- W1803779312
- Cited by
- 423
- References
- 244
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 22 · 2023: 25 · 2022: 32 · 2021: 36 · 2020: 31 · 2019: 40 · 2018: 34 · 2017: 35 · 2016: 28 · 2015: 29 · 2014: 38 · 2013: 30 · 2012: 8
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroendocrinology (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Centre National de la Recherche Scientifique
- National Institute of General Medical Sciences (GM25280, R01GM025280)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- oxytocin, vasopressin, vasopressin receptor, oxytocin receptor, V1a receptor, V1b receptor, V2 receptor, peptide agonists, peptide antagonists, conivaptan, tolvaptan, fluorescent ligands, receptor localization, receptor dimerization, oxytocin analogues, receptor selectivity, species differences
- MeSH terms
- Animals, Arginine Vasopressin, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Oxytocin, Structure-Activity Relationship, Receptors, Vasopressin, Receptors, Oxytocin, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
